PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31969819-8 2019 Fluoxetine, simvastatin, and resveratrol significantly inhibited this IL-1beta- and TNF-alpha-induced ET-1 production. Simvastatin 12-23 tumor necrosis factor Homo sapiens 84-93 33542676-11 2021 The data revealed that simvastatin could inhibit TNF-alpha-induced CYR61 expression by modulating the activity of transcription factor FoxO3a. Simvastatin 23-34 tumor necrosis factor Homo sapiens 49-58 32892025-6 2020 Additionally, DEHP abolished the anti-inflammatory effect of simvastatin on the tumor necrosis factor alpha-induced upregulation of adhesion molecules and monocyte adhesion to ECs. Simvastatin 61-72 tumor necrosis factor Homo sapiens 80-107 29604489-0 2018 Attenuation of TNF-induced neutrophil adhesion by simvastatin is associated with the inhibition of Rho-GTPase activity, p50 activity and morphological changes. Simvastatin 50-61 tumor necrosis factor Homo sapiens 15-18 29604489-7 2018 Accordingly, the TNF-induced elevation of neutrophil p50 activity was abolished by simvastatin. Simvastatin 83-94 tumor necrosis factor Homo sapiens 17-20 29604489-9 2018 Simvastatin appears to inhibit neutrophil adhesion by interfering in TNF-induced cytoskeletal rearrangements, in association with the inhibition of Rho A activity, NFkappaB translocation and, consequently, beta2-integrin activity. Simvastatin 0-11 tumor necrosis factor Homo sapiens 69-72 31752013-9 2019 Simvastatin was associated with suppression of miR-155 expression in HUVECs following TNF-alpha treatment, and with a corresponding reduction in TNF-alpha-induced senescence, whereas miR-155 overexpression had the opposite effect. Simvastatin 0-11 tumor necrosis factor Homo sapiens 86-95 31752013-9 2019 Simvastatin was associated with suppression of miR-155 expression in HUVECs following TNF-alpha treatment, and with a corresponding reduction in TNF-alpha-induced senescence, whereas miR-155 overexpression had the opposite effect. Simvastatin 0-11 tumor necrosis factor Homo sapiens 145-154 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Simvastatin 21-32 tumor necrosis factor Homo sapiens 159-162 29389739-0 2018 Simvastatin Modulates Interaction Between Vascular Smooth Muscle Cell/Macrophage and TNF-alpha-Activated Endothelial Cell. Simvastatin 0-11 tumor necrosis factor Homo sapiens 85-94 29389739-3 2018 The purpose of this study was to investigate the effects of simvastatin on VSMC/macrophage functions, which are induced by TNF-alpha-activated EC in coculture system in vitro. Simvastatin 60-71 tumor necrosis factor Homo sapiens 123-132 29389739-4 2018 The results showed that under noncontacting conditions, simvastatin could reduce the proliferation, apoptosis, and TNF-alpha, IL-6, and vascular endothelial growth factor secretion both in VSMC and macrophage, which is induced by TNF-alpha-activated EC. Simvastatin 56-67 tumor necrosis factor Homo sapiens 115-124 29389739-4 2018 The results showed that under noncontacting conditions, simvastatin could reduce the proliferation, apoptosis, and TNF-alpha, IL-6, and vascular endothelial growth factor secretion both in VSMC and macrophage, which is induced by TNF-alpha-activated EC. Simvastatin 56-67 tumor necrosis factor Homo sapiens 230-239 29604489-2 2018 Previous studies have shown that simvastatin, a statin with known pleiotropic anti-inflammatory properties, can partially abrogate the effects of TNF-induced neutrophil adhesion, in association with the modulation of beta2-integrin expression. Simvastatin 33-44 tumor necrosis factor Homo sapiens 146-149 29604489-4 2018 A microfluidic assay confirmed the ability of simvastatin to inhibit TNF-induced human neutrophil adhesion to fibronectin ligand under conditions of shear stress, while intravital imaging microscopy demonstrated an abrogation of leukocyte recruitment by simvastatin in the microvasculature of mice that had received a TNF stimulus. Simvastatin 46-57 tumor necrosis factor Homo sapiens 69-72 29604489-4 2018 A microfluidic assay confirmed the ability of simvastatin to inhibit TNF-induced human neutrophil adhesion to fibronectin ligand under conditions of shear stress, while intravital imaging microscopy demonstrated an abrogation of leukocyte recruitment by simvastatin in the microvasculature of mice that had received a TNF stimulus. Simvastatin 254-265 tumor necrosis factor Homo sapiens 69-72 28546421-5 2017 Simvastatin or mevastatin significantly suppressed the effects of ox-LDL or TNFalpha Promoter reporter assays and small interfering RNA knockdown revealed that statins inhibit ox-LDL-mediated NLRP3 inflammasome activation via the pregnane X receptor (PXR). Simvastatin 0-11 tumor necrosis factor Homo sapiens 76-84 29250545-10 2017 Simvastatin significantly reduced the levels of cTnT, CK-MB, TNF-alpha, IL-6, and IL-8 (P < 0.05), reduced the expression of LC3-II/LC3-I and Beclin 1, and increased the expression of phosphorylation of AMPK. Simvastatin 0-11 tumor necrosis factor Homo sapiens 61-70 26884290-7 2016 In turn, the effect of fenofibrate, alone or in combination with simvastatin, on TNF-alpha, interleukin-6, and hsCRP, but not on interleukin-1beta and MCP-1, was stronger in patients aged between 50 and 75 years, and correlated with an improvement in insulin sensitivity only in this age group. Simvastatin 65-76 tumor necrosis factor Homo sapiens 81-90 26911804-0 2016 Simvastatin in combination with bergamottin potentiates TNF-induced apoptosis through modulation of NF-kappaB signalling pathway in human chronic myelogenous leukaemia. Simvastatin 0-11 tumor necrosis factor Homo sapiens 56-59 27086089-11 2016 Plasma concentrations of IL-6, IL-8, and TNFalpha, and peritoneal concentrations of IL-6 and IL-8, were significantly lower in the simvastatin group postoperatively. Simvastatin 131-142 tumor necrosis factor Homo sapiens 41-49 26884289-6 2016 In both age groups, simvastatin reduced plasma levels of hsCRP, leptin, visfatin, and TNF-alpha and increased circulating levels of adiponectin. Simvastatin 20-31 tumor necrosis factor Homo sapiens 86-95 27818195-9 2016 Functionally, hypotonic solution increased the TNF-alpha mRNA expression, which could be decreased by tiron, DPI, NPPB, DIDS and simvastatin but not pravastatin. Simvastatin 129-140 tumor necrosis factor Homo sapiens 47-56 27650878-11 2016 Atorvastatin and simvastatin suppressed the DC maturation showing lower expression of CD80, CD83, and CD86, and limited their production of tumor necrosis factor-alpha, IL-1beta and IL-6, and increased transforming growth factor-beta and IL-10 secretion. Simvastatin 17-28 tumor necrosis factor Homo sapiens 140-167 26322850-3 2015 A short pretreatment with simvastatin dose-dependently inhibited the production of tumor necrosis factor (TNF)-alpha in response to TLR8 activation (but not TLR2, -4 or -5). Simvastatin 26-37 tumor necrosis factor Homo sapiens 83-116 27213056-10 2016 Simvastatin treatment significantly increased FMD value, decreased CRP and TNF-alpha concentration. Simvastatin 0-11 tumor necrosis factor Homo sapiens 75-84 26322850-7 2015 Simvastatin significantly inhibited the spontaneous release of TNF in this model, which was not reversed by mevalonate. Simvastatin 0-11 tumor necrosis factor Homo sapiens 63-66 25704622-8 2015 Pre-treatment with simvastatin (S-L) reduced IL-6 (P = 0.02), TNF-alpha (P = 0.02), and MMP-9 (P = 0.01); post-treatment (L-S) reduced IL-1beta (P = 0.02) and TNF-alpha (P = 0.04), while simultaneous treatment (L+S) did not reduce any of the cytokines tested. Simvastatin 19-30 tumor necrosis factor Homo sapiens 62-71 25704622-8 2015 Pre-treatment with simvastatin (S-L) reduced IL-6 (P = 0.02), TNF-alpha (P = 0.02), and MMP-9 (P = 0.01); post-treatment (L-S) reduced IL-1beta (P = 0.02) and TNF-alpha (P = 0.04), while simultaneous treatment (L+S) did not reduce any of the cytokines tested. Simvastatin 19-30 tumor necrosis factor Homo sapiens 159-168 25704622-9 2015 Simvastatin reduced the molar ratio of TNF-alpha/sTNFR1 or R2 and IL-1beta/sIL-1R2 (P = 0.01 and 0.04 in S-L group; P = 0.01 and 0.004 in L-S group, respectively). Simvastatin 0-11 tumor necrosis factor Homo sapiens 39-48 25993292-4 2015 Simvastatin strongly inhibited the activation of nuclear factor (NF)-kappaB induced by tumor necrosis factor (TNF)-alpha in human AAA walls, but showed little effect on c-jun N-terminal kinase (JNK) activation. Simvastatin 0-11 tumor necrosis factor Homo sapiens 87-120 26091905-0 2015 The effect of simvastatin treatment on endothelial cell response to shear stress and tumor necrosis factor alpha stimulation. Simvastatin 14-25 tumor necrosis factor Homo sapiens 85-112 25993292-5 2015 Simvastatin, as well as pitavastatin significantly reduced the secretion of matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-2 and epithelial neutrophil-activating peptide (CXCL5) under both basal and TNF-alpha-stimulated conditions. Simvastatin 0-11 tumor necrosis factor Homo sapiens 225-234 26136131-5 2015 Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups. Simvastatin 0-11 tumor necrosis factor Homo sapiens 102-111 26136131-5 2015 Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups. Simvastatin 30-41 tumor necrosis factor Homo sapiens 102-111 26136131-8 2015 The impact of simvastatin administered together with fenofibrate on TNF-alpha, interleukin-1beta, and hsCRP was also stronger in the men than in the women, but the difference did not reach the level of significance. Simvastatin 14-25 tumor necrosis factor Homo sapiens 68-77 25149995-6 2014 Apart from decreasing plasma total cholesterol, LDL cholesterol and apolipoprotein B-100 levels, simvastatin reduced plasma levels of FFA, leptin and TNF-alpha, as well as increased plasma levels of adiponectin, which was accompanied by a reduction in plasma CRP. Simvastatin 97-108 tumor necrosis factor Homo sapiens 150-159 25931040-5 2015 Administration of simvastatin and statin/ezetimibe combination for 30 days reduced plasma levels of hsCRP, FFA, leptin, visfatin, and TNF-alpha but increased plasma levels of adiponectin, while the effect of ezetimibe was much more limited. Simvastatin 18-29 tumor necrosis factor Homo sapiens 134-143 27012115-7 2015 The significant decrease of hs-CRP (p = 0.017) and TNFalpha (p = 0.003) concentration after simvastatin was found in smokers, and 8-iso-PGF2alpha in smokers and 192QQ allele carriers (p = 0.038). Simvastatin 92-103 tumor necrosis factor Homo sapiens 51-59 24718722-0 2014 Simvastatin attenuates TNF-alpha-induced apoptosis in endothelial progenitor cells via the upregulation of SIRT1. Simvastatin 0-11 tumor necrosis factor Homo sapiens 23-32 24718722-8 2014 The aim of this study was to demonstrate the effectiveness of one of the most commonly used statins, simvastatin, on decreasing TNF-alpha-induced apoptosis in EPCs. Simvastatin 101-112 tumor necrosis factor Homo sapiens 128-137 24788303-6 2014 The expression of important pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6 and interferon-gamma), which was quantified using ELISA showed that simvastatin decreased the expression of pro-inflammatory cytokines to an average of 2-fold. Simvastatin 167-178 tumor necrosis factor Homo sapiens 56-83 24718722-9 2014 The results indicated that SIRT1 protein expression was decreased by TNF-alpha in a time- and dose-dependent manner and that while TNF-alpha caused a marked increase in the percentage of apoptotic EPCs, application of simvastatin decreased this percentage. Simvastatin 218-229 tumor necrosis factor Homo sapiens 69-78 24718722-11 2014 In conclusion, findings of this study showed that simvastatin is crucial in counteracting the TNF-alpha-induced apoptosis of EPCs and that this protection may involve the actions of SIRT1. Simvastatin 50-61 tumor necrosis factor Homo sapiens 94-103 22915623-11 2013 Simvastatin enhanced the expression of CD39 and thrombomodulin mRNA initially reduced by IL-17 and TNF-alpha combination. Simvastatin 0-11 tumor necrosis factor Homo sapiens 99-108 24392131-13 2014 Simvastatin (1.0 microM) significantly reduced the TNF-alpha-induced NF-kappaB activation in cultured optic nerve astrocytes. Simvastatin 0-11 tumor necrosis factor Homo sapiens 51-60 25185849-6 2014 Administration of simvastatin and ezetimibe for 30 days reduced plasma levels of leptin, visfatin, TNF-alpha, as well as increased plasma levels of adiponectin. Simvastatin 18-29 tumor necrosis factor Homo sapiens 99-108 24028188-6 2013 Simvastatin significantly attenuated TNF-alpha-induced CCL2 secretion without affecting CCL2 mRNA or protein expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 37-46 24354929-5 2014 RESULTS: Apart from improving lipid profile, simvastatin administered alone or in combination with ezetimibe, decreased plasma levels of hsCRP, FFA, leptin, visfatin, and TNF-alpha, as well as increased plasma levels of adiponectin. Simvastatin 45-56 tumor necrosis factor Homo sapiens 171-180 22915623-0 2013 Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-alpha on endothelial cells. Simvastatin 0-11 tumor necrosis factor Homo sapiens 82-91 22915623-4 2013 METHODS: The effect of simvastatin was assessed in human umbilical vein endothelial cells treated by IL-17 alone or combined with tumour necrosis factor (TNF)-alpha, with or without mevalonate, an inhibitor of simvastatin. Simvastatin 23-34 tumor necrosis factor Homo sapiens 130-164 22915623-14 2013 Finally, simvastatin had an additive effect with infliximab to decrease the effect of the combination of IL-17 and TNF-alpha on IL-6 mRNA expression. Simvastatin 9-20 tumor necrosis factor Homo sapiens 115-124 23159435-4 2013 RESULTS: Simvastatin, but not placebo, reduced monocyte release of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta and monocyte chemoattractant protein-1, as well decreased plasma levels of C-reactive protein. Simvastatin 9-20 tumor necrosis factor Homo sapiens 67-94 23250325-4 2013 RESULTS: In the presence of a TNF-alpha inflammatory stimulus, neutrophils displayed a rapid and substantial enhancement in their adhesive properties that was abrogated by preincubation of cells with simvastatin. Simvastatin 200-211 tumor necrosis factor Homo sapiens 30-39 23376721-3 2013 The aim of this study is to evaluate the effect of simvastatin on the ox-LDL-induced ER stress and expression and secretion of TNF-alpha and MCP-1 in 3T3-L1 adipocytes. Simvastatin 51-62 tumor necrosis factor Homo sapiens 127-136 23376721-11 2013 Simvastatin could inhibit ox-LDL-induced ER stress and reduce the expression of TNF-alpha and MCP-1 at mRNA and protien level in dose dependent manner. Simvastatin 0-11 tumor necrosis factor Homo sapiens 80-89 22694979-5 2012 RESULTS: Treatment with simvastatin resulted in a decrease in 4-HNE and TNF-alpha concentration (median 4.18 mug/mg protein vs. 4.75, p = 0.012; median 10.33 pg/ml vs. 11.81, p = 0.026, respectively). Simvastatin 24-35 tumor necrosis factor Homo sapiens 72-81 23950601-4 2013 RESULTS: Ninety-day simvastatin treatment reduced lymphocyte release of TNF-alpha, interleukin-2 and interferon-gamma, which was accompanied by a decrease in plasma C-reactive protein. Simvastatin 20-31 tumor necrosis factor Homo sapiens 72-81 23108656-10 2012 Moreover, we observed that simvastatin attenuated tumor necrosis factor-alpha-induced upregulation of miR-155 and ameliorated the effects of tumor necrosis factor-alpha on eNOS expression and endothelium-dependent vasodilation. Simvastatin 27-38 tumor necrosis factor Homo sapiens 50-77 23108656-10 2012 Moreover, we observed that simvastatin attenuated tumor necrosis factor-alpha-induced upregulation of miR-155 and ameliorated the effects of tumor necrosis factor-alpha on eNOS expression and endothelium-dependent vasodilation. Simvastatin 27-38 tumor necrosis factor Homo sapiens 141-168 22658637-10 2012 Simvastatin also attenuated the increase in expression and secretion of PAI-1 induced by TNF-alpha (16898.6 +- 1663.3 vs 12922.1 +- 843.9 and 5.19 +- 3.12 vs 0.59 +- 0.16, respectively p<0.05), but under baseline conditions had no effect on the expression or secretion of PAI-1. Simvastatin 0-11 tumor necrosis factor Homo sapiens 89-98 22658637-12 2012 CONCLUSIONS: Our findings suggested that simvastatin counteracted the stimulatory effect of TNF-alpha on secretion and expression of MCP-1, PAI-1 and adiponectin, implying a potential anti-atherogenic effect during the inflammatory process; these pleitropic effects were more pronounced with HMG-CoA reductase inhibitor. Simvastatin 41-52 tumor necrosis factor Homo sapiens 92-101 22974127-10 2012 Simvastatin treatment resulted in increased mRNA and protein expression of molecules such as TNF, Fas-L, Traf1 and cleaved caspase 8, major mediators of intrinsic apoptosis pathway and reduced protein levels of pro-survival genes Lhx4 and Nme5. Simvastatin 0-11 tumor necrosis factor Homo sapiens 93-96 22694979-9 2012 CONCLUSION: Simvastatin inhibits free radicals and TNF-alpha generation and improves antioxidant capacity of human AAA wall tissue, possibly through the suppression of NF-kappaB activity. Simvastatin 12-23 tumor necrosis factor Homo sapiens 51-60 22405819-10 2012 Simvastatin blocked the TNF-alpha suppressive effect on thrombomodulin and eNOS, irrespective of shear stress. Simvastatin 0-11 tumor necrosis factor Homo sapiens 24-33 22405819-11 2012 The strong inductive effect of TNF-alpha on VCAM-1 was counteracted by simvastatin and shear stress in an additive dose-response dependent way. Simvastatin 71-82 tumor necrosis factor Homo sapiens 31-40 20473500-8 2011 SMV mitigated PG-induced increase in RhoA activity and NF-kappaB activation as well as secretion of TNFalpha and IL-1beta. Simvastatin 0-3 tumor necrosis factor Homo sapiens 100-108 21925249-5 2011 Moreover, simvastatin significantly inhibited LPS-induced inducible nitric oxide synthase (NOS) expression, and formation of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), nitrite and free radicals, but enhanced interleukin-10 (IL-10) production. Simvastatin 10-21 tumor necrosis factor Homo sapiens 163-190 21925249-5 2011 Moreover, simvastatin significantly inhibited LPS-induced inducible nitric oxide synthase (NOS) expression, and formation of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), nitrite and free radicals, but enhanced interleukin-10 (IL-10) production. Simvastatin 10-21 tumor necrosis factor Homo sapiens 192-201 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Simvastatin 0-11 tumor necrosis factor Homo sapiens 58-85 22027793-4 2011 RESULTS: At the end of 12 months, the patients in simvastatin group showed significantly reduced total cholesterol, LDL-C, CRP, TNF-alpha, and (99)Tc(m)-MIBI uptake fraction. Simvastatin 50-61 tumor necrosis factor Homo sapiens 128-137 20607595-5 2011 The ex vivo release of IL-1beta and IL-6 was not altered by simvastatin, whereas the release of TNF-alpha and IL-8 increased after 6 weeks of simvastatin treatment. Simvastatin 142-153 tumor necrosis factor Homo sapiens 96-105 21367616-1 2011 PURPOSE: To assess the in vitro effects of simvastatin on IL-10 and TNF-alpha secretion from peripheral blood mononuclear cells (PBMC) of critically ill patients with and without acute kidney injury (AKI). Simvastatin 43-54 tumor necrosis factor Homo sapiens 68-77 21367616-8 2011 The simultaneous incubation with LPS and simvastatin caused decreased IL-10 production in cells from patients compared to control (337 (135-626) vs 540 (345-871) pg/mL, p<0.05) and increased TNF-alpha release (711 (619-832) vs 324 (155-355) pg/mL, p<0.05). Simvastatin 41-52 tumor necrosis factor Homo sapiens 194-203 19932975-0 2010 Effect of simvastatin on endothelial cell apoptosis mediated by Fas and TNF-alpha. Simvastatin 10-21 tumor necrosis factor Homo sapiens 72-81 20863785-5 2010 In static culture, simvastatin potentiated the TNFalpha-induced increase in VCAM-1 and ICAM-1 mRNA but not total protein at 24 h. Mevalonate, a precursor to cholesterol biosynthesis, eliminated the effect of simvastatin. Simvastatin 19-30 tumor necrosis factor Homo sapiens 47-55 20863785-5 2010 In static culture, simvastatin potentiated the TNFalpha-induced increase in VCAM-1 and ICAM-1 mRNA but not total protein at 24 h. Mevalonate, a precursor to cholesterol biosynthesis, eliminated the effect of simvastatin. Simvastatin 208-219 tumor necrosis factor Homo sapiens 47-55 20863785-8 2010 We conclude that simvastatin enhances VCAM-1 and ICAM-1 gene expression in TNFalpha-activated endothelial cells through inhibition of HMG-CoA reductase. Simvastatin 17-28 tumor necrosis factor Homo sapiens 75-83 21173096-2 2011 We investigated, in vitro, the adhesion molecules involved in endothelial-sickle cell disease neutrophil interactions and the effect of simvastatin on sickle cell disease neutrophil adhesion to tumor necrosis factor-alpha-activated endothelial monolayers (human umbilical vein endothelial cells), and neutrophil chemotaxis. Simvastatin 136-147 tumor necrosis factor Homo sapiens 194-221 21173096-10 2011 Furthermore, intercellular adhesion molecule-1 expression was significantly abrogated on tumor necrosis factor-alpha-stimulated endothelium incubated with simvastatin, and statin treatment inhibited the interleukin-8-stimulated migration of both control and sickle cell disease neutrophils. Simvastatin 155-166 tumor necrosis factor Homo sapiens 89-116 20676966-4 2010 The results showed that lycopene and simvastatin applied together reduced TNFalpha and IFNgamma secretion, and abolished the increased production of the proinflammatory cytokine IL-1gamma caused by incubation with simvastatin only, an observation suggesting that simultaneous administration of both substances may reduce inflammatory responses. Simvastatin 37-48 tumor necrosis factor Homo sapiens 74-82 20097734-4 2010 We found that both AGGC, which inhibits CAAX carboxyl methylation, and simvastatin, which inhibits CAAX geranylgeranylation, caused relocalization of GRP94, calnexin, and calreticulin, effects that were not seen during endothelial apoptosis induced by TNF-alpha or ultraviolet (UV) irradiation. Simvastatin 71-82 tumor necrosis factor Homo sapiens 252-261 19932975-8 2010 Further, simvastatin increased LSEC-apoptosis induced by Fas and TNF-alpha. Simvastatin 9-20 tumor necrosis factor Homo sapiens 65-74 19932975-9 2010 Mevalonate and GGPP partially prevented simvastatin-induced sensitization to LSEC death mediated by Jo2 and TNF-alpha, but not Jo2 alone. Simvastatin 40-51 tumor necrosis factor Homo sapiens 108-117 19205663-11 2009 Both TNF-alpha and IL-6 levels were significantly reduced in the simvastatin group (p = 0.02 and p = 0.02, respectively), while no such difference was observed in the placebo group (p = 0.35 and 0.39, respectively). Simvastatin 65-76 tumor necrosis factor Homo sapiens 5-14 19481207-10 2009 Simvastatin (1 micromol/L) suppressed the non-uniform shear stress- and TNF-alpha-induced increase in monocytic cell adhesion by about 30% via inhibition of VCAM-1 expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 72-81 19008785-8 2009 Our data suggest that simvastatin, despite lowering circulating low-density lipoprotein cholesterol, decreased LPS toxicity by reduction of NF-kappaB activation and subsequent release of TNF by modulating 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and therefore deserves consideration as a possible adjuvant therapy in acute inflammatory disease. Simvastatin 22-33 tumor necrosis factor Homo sapiens 187-190 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 tumor necrosis factor Homo sapiens 117-144 17519305-12 2007 Simvastatin therapy significantly inhibited lipopolysaccharide-activated monocyte release of O(2)(-) (P < 0.0005), IL-8 (P < 0.03), and TNF (P < 0.02). Simvastatin 0-11 tumor necrosis factor Homo sapiens 142-145 18365690-4 2008 Furthermore, exogenously applied mevalonate or geranylgeranylpyrophosphate in combination with simvastatin completely prevented the inhibitory effects of simvastatin on ROS generation and monocyte-endothelial cell adhesion by TNFalpha and Ang II. Simvastatin 95-106 tumor necrosis factor Homo sapiens 226-234 18365690-4 2008 Furthermore, exogenously applied mevalonate or geranylgeranylpyrophosphate in combination with simvastatin completely prevented the inhibitory effects of simvastatin on ROS generation and monocyte-endothelial cell adhesion by TNFalpha and Ang II. Simvastatin 154-165 tumor necrosis factor Homo sapiens 226-234 18365690-5 2008 These results suggest that monocyte adhesion to endothelial cells induced by TNF-alpha or Ang II is mediated via the geranylgeranyl isoprenoid-dependent generation of ROS, and that this is inhibited by simvastatin. Simvastatin 202-213 tumor necrosis factor Homo sapiens 77-86 18203325-2 2008 We have also reported that a certain pharmacological concentration of simvastatin, i.e., 0.05-0.1 microM, inhibits the production of interleukin 6 (IL-6) and IL-8 and the cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) derived from patients with RA in vitro. Simvastatin 70-81 tumor necrosis factor Homo sapiens 201-228 18203325-2 2008 We have also reported that a certain pharmacological concentration of simvastatin, i.e., 0.05-0.1 microM, inhibits the production of interleukin 6 (IL-6) and IL-8 and the cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) derived from patients with RA in vitro. Simvastatin 70-81 tumor necrosis factor Homo sapiens 230-239 18203325-11 2008 CONCLUSION: These data, together with our previous report, suggest that low (pharmacological range) and high concentrations of simvastatin affect FLS differently: (1) at a low concentration, it inhibits IL-6 and IL-8 production and the cell proliferation of FLS induced by TNF-alpha (2) at high concentrations, it induces apoptosis in FLS. Simvastatin 127-138 tumor necrosis factor Homo sapiens 273-282 17716606-0 2007 High dosage of simvastatin reduces TNF-alpha-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1beta in vitro. Simvastatin 15-26 tumor necrosis factor Homo sapiens 35-44 17716606-10 2007 A preconditioning with simvastatin [25 microM] resulted in significant inhibition of the TNF-alpha-induced apoptosis, whereas the IL-1beta-mediated apoptosis was only slightly reduced. Simvastatin 23-34 tumor necrosis factor Homo sapiens 89-98 17716606-11 2007 In conclusion, this study shows clearly that TNF-alpha and IL-1beta are harmful to early EPC and that the HMG-CoA reductase inhibitor simvastatin protects EPC from TNF-alpha- and eventually from IL-1beta-mediated apoptosis. Simvastatin 134-145 tumor necrosis factor Homo sapiens 164-173 19410078-3 2009 The study assessed the effect of simvastatin on tumor necrosis factor alpha (TNF- alpha)-induced synthesis of Cyr61 and CCL2 in MG-63 human osteoblastic cells. Simvastatin 33-44 tumor necrosis factor Homo sapiens 48-75 19410078-3 2009 The study assessed the effect of simvastatin on tumor necrosis factor alpha (TNF- alpha)-induced synthesis of Cyr61 and CCL2 in MG-63 human osteoblastic cells. Simvastatin 33-44 tumor necrosis factor Homo sapiens 77-87 18830905-7 2009 Anti-CD3-stimulated IL-10 and tumour necrosis factor (TNF)alpha production by PBMCs was upregulated after simvastatin therapy. Simvastatin 106-117 tumor necrosis factor Homo sapiens 54-63 18976673-8 2008 However, simvastatin inhibited this promotion (2.5+/-0.3 mm, p<0.001 vs. TNF-alpha alone) by decreasing oxidative stress, VEGF, Akt, and eNOS. Simvastatin 9-20 tumor necrosis factor Homo sapiens 76-85 18635600-7 2008 TNF-alpha/LPS and H2O2 further enhanced MSH2 expression in both control and CD cells, which were decreased by simvastatin. Simvastatin 110-121 tumor necrosis factor Homo sapiens 0-9 18365690-0 2008 Inhibitory effect of simvastatin on the TNF-alpha- and angiotensin II-induced monocyte adhesion to endothelial cells is mediated through the suppression of geranylgeranyl isoprenoid-dependent ROS generation. Simvastatin 21-32 tumor necrosis factor Homo sapiens 40-49 18365690-2 2008 Simvastatin, a HMG-CoA reductase inhibitor, suppressed both tumor necrosis factor (TNF)-alpha- and angiotensin (Ang) II-induced monocyte adhesion to endothelial cells (an initial step in vascular inflammation) and reactive oxygen species (ROS) production. Simvastatin 0-11 tumor necrosis factor Homo sapiens 60-93 17901590-9 2007 In OE-19 cells, the COX-2 expression was detected and significantly increased by the addition of TNFalpha into the medium, however, this effect was significantly attenuated by simvastatin. Simvastatin 176-187 tumor necrosis factor Homo sapiens 97-105 17560598-0 2007 Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. Simvastatin 0-11 tumor necrosis factor Homo sapiens 21-29 17560598-2 2007 We have previously reported that simvastatin inhibits tumor necrosis factor-alpha (TNFalpha)-induced cardiac myofibroblast invasion and MMP-9 secretion, key events in this remodeling process. Simvastatin 33-44 tumor necrosis factor Homo sapiens 83-91 17560598-12 2007 In summary, simvastatin reduces TNFalpha-induced invasion of human cardiac myofibroblasts through two distinct mechanisms: (i) by attenuating cell migration via Rho-kinase inhibition and subsequent cytoskeletal disruption, and (ii) by decreasing MMP-9 secretion via a post-transcriptional mechanism. Simvastatin 12-23 tumor necrosis factor Homo sapiens 32-40 17464346-11 2007 Simvastatin (0.1, 0.5, or 2.5 micromol/L) markedly inhibited the elevated concentrations of TNF-alpha and sICAM-1, the activity of NF-kappaB, and the phosphorylation of p38 MAPK and ERK(1/2) induced by ADMA. Simvastatin 0-11 tumor necrosis factor Homo sapiens 92-101 17172275-10 2007 Simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, which is known to activate PI3K/Akt, blocks TNF-alpha- and insulin-induced PAI-1 expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 111-120 17172275-11 2007 Treatment with PI3K inhibitors reversed the inhibitor effects of simvastatin on TNF-alpha- and insulin-induced PAI-1 expression. Simvastatin 65-76 tumor necrosis factor Homo sapiens 80-89 16942919-3 2007 Simvastatin treatment did not inhibit AgLDL-induced macrophage lipid accumulation, but significantly increased the secretion of IL-1beta and IL-8 from macrophages, whilst inhibiting the secretion of tumor necrosis factor-alpha (TNF-alpha) and having no significant effect on IL-6 secretion. Simvastatin 0-11 tumor necrosis factor Homo sapiens 199-226 17277159-0 2007 Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. Simvastatin 0-11 tumor necrosis factor Homo sapiens 24-33 17277159-2 2007 Therefore, in this article, we investigated the effects of simvastatin on TNF-alpha-induced cell signaling. Simvastatin 59-70 tumor necrosis factor Homo sapiens 74-83 17277159-3 2007 We found that simvastatin potentiated the apoptosis induced by TNF-alpha as indicated by intracellular esterase activity, caspase activation, TUNEL, and annexin V staining. Simvastatin 14-25 tumor necrosis factor Homo sapiens 63-72 17277159-7 2007 Simvastatin inhibited TNF-alpha-induced IkappaBalpha kinase activation, which led to inhibition of IkappaBalpha phosphorylation and degradation, suppression of p65 phosphorylation, and translocation to the nucleus. Simvastatin 0-11 tumor necrosis factor Homo sapiens 22-31 16942919-3 2007 Simvastatin treatment did not inhibit AgLDL-induced macrophage lipid accumulation, but significantly increased the secretion of IL-1beta and IL-8 from macrophages, whilst inhibiting the secretion of tumor necrosis factor-alpha (TNF-alpha) and having no significant effect on IL-6 secretion. Simvastatin 0-11 tumor necrosis factor Homo sapiens 228-237 18260853-10 2007 At the background of therapy with simvastatin we noted significant lowering of proinflammatory cytokines (TNFalpha, IL-1beta, IL-6, IL-8) in blood serum irrespective of level of low density lipoprotein cholesterol, betterment of functional state of the left ventricle, positive clinical dynamics of CHF. Simvastatin 34-45 tumor necrosis factor Homo sapiens 106-114 16529752-11 2007 We conclude that cerivastatin and simvastatin reduce TNF-alpha-induced up-regulation of ICAM-1 and VCAM-1 surface expression via increased protein shedding mediated by HMG-CoA reductase inhibition and subsequent isoprenoid depletion. Simvastatin 34-45 tumor necrosis factor Homo sapiens 53-62 17377212-0 2007 Simvastatin-induced prevention of the increase in TNF-alpha level in the acute phase of ischemic stroke. Simvastatin 0-11 tumor necrosis factor Homo sapiens 50-59 17377212-2 2007 The aim of this study was to evaluate the influence of early treatment with simvastatin, an HMG-CoA reductase inhibitor, on serum TNF-alpha level in acute ischemic stroke (AIS). Simvastatin 76-87 tumor necrosis factor Homo sapiens 130-139 17377212-5 2007 Serum TNF-alpha level was significantly elevated on day 3 after the stroke onset in comparison to day 1 only in the simvastatin-treated group (increase in median values by 16.2% [p = 0.028] and 6.1% within 3 days in Group II and I, respectively). Simvastatin 116-127 tumor necrosis factor Homo sapiens 6-15 17377212-6 2007 These findings indicate that simvastatin given within 24 h after the onset of stroke could prevent the increase in serum TNF-alpha level within 3 days. Simvastatin 29-40 tumor necrosis factor Homo sapiens 121-130 17853009-12 2007 CONCLUSIONS: Simvastatin decreased the serum TNF-alpha level in PD patients with a non-inflammatory status. Simvastatin 13-24 tumor necrosis factor Homo sapiens 45-54 17853009-13 2007 A decrease in the TNF-alpha level could be one of the possible mechanisms of the anti-atherogeneic effect of simvastatin. Simvastatin 109-120 tumor necrosis factor Homo sapiens 18-27 17075836-0 2006 RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Simvastatin 124-135 tumor necrosis factor Homo sapiens 15-42 17075836-8 2006 SMV prevented the increase in NF-kappaB activation and rise in IL-1beta and IL-6 levels induced by TNFalpha, whereas mevalonate and geranylgeranyl pyrophosphate reversed the inhibitory effects of SMV on activation of NF-kappaB and RhoA. Simvastatin 0-3 tumor necrosis factor Homo sapiens 99-107 17086617-0 2006 Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin. Simvastatin 143-154 tumor necrosis factor Homo sapiens 0-27 16978784-6 2006 The simvastatin treatment significantly diminished the microglial CCL5 expression induced by IFN-beta alone or by IFN-beta/TNF-alpha combination. Simvastatin 4-15 tumor necrosis factor Homo sapiens 123-132 16978784-7 2006 In the presence of simvastatin, the IFN-beta-induced activation of Janus kinase (Jak)-signal transducer and activator of transcription (STAT) pathway was attenuated, although this compound had little or no effect on the TNF-alpha-evoked activation of nuclear factor kappaB and c-Jun N-terminal kinase pathways. Simvastatin 19-30 tumor necrosis factor Homo sapiens 220-229 16557230-8 2006 Simvastatin attenuated CLP-induced tubular damage and reversed CLP-induced reduction of intrarenal microvascular perfusion and renal tubular hypoxia at 24 h. Simvastatin also restored towards normal CLP-induced renal vascular protein leak and serum TNF-alpha. Simvastatin 0-11 tumor necrosis factor Homo sapiens 249-258 16870268-5 2006 Simvastatin inhibited IFN-gamma, TNF-alpha, and IL-2 secretion, as well as the expression of T-bet, a transcription factor that regulates Th1 cell differentiation. Simvastatin 0-11 tumor necrosis factor Homo sapiens 33-42 16740276-2 2006 Here we demonstrate that the HMG-CoA reductase inhibitor simvastatin potentiates TNFalpha-mediated apoptosis and TNFalpha signaling in human umbilical vein endothelial cells (HUVECs). Simvastatin 57-68 tumor necrosis factor Homo sapiens 81-89 16740276-2 2006 Here we demonstrate that the HMG-CoA reductase inhibitor simvastatin potentiates TNFalpha-mediated apoptosis and TNFalpha signaling in human umbilical vein endothelial cells (HUVECs). Simvastatin 57-68 tumor necrosis factor Homo sapiens 113-121 16740276-3 2006 While 2.5 microM simvastatin or 40 ng/ml TNFalpha alone had only a small effect on apoptosis in HUVECs, co-incubation with simvastatin and TNFalpha markedly increased apoptosis in a time- and dose-dependent manner as measured by FACS analysis of propidium iodide-stained cells. Simvastatin 17-28 tumor necrosis factor Homo sapiens 139-147 16740276-3 2006 While 2.5 microM simvastatin or 40 ng/ml TNFalpha alone had only a small effect on apoptosis in HUVECs, co-incubation with simvastatin and TNFalpha markedly increased apoptosis in a time- and dose-dependent manner as measured by FACS analysis of propidium iodide-stained cells. Simvastatin 123-134 tumor necrosis factor Homo sapiens 41-49 16740276-6 2006 Furthermore, simvastatin increased the expression of the TNFalpha type I receptor (TNFalphaRI) with a dose dependence and a dependence on geranylgeranylation similar to that demonstrated for the potentiation of TNFalpha-mediated apoptosis. Simvastatin 13-24 tumor necrosis factor Homo sapiens 57-65 16740276-6 2006 Furthermore, simvastatin increased the expression of the TNFalpha type I receptor (TNFalphaRI) with a dose dependence and a dependence on geranylgeranylation similar to that demonstrated for the potentiation of TNFalpha-mediated apoptosis. Simvastatin 13-24 tumor necrosis factor Homo sapiens 83-91 16740276-8 2006 Simvastatin also potentiated TNFalpha signaling as determined by increased TNFalpha-mediated E-selectin expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 29-37 16740276-8 2006 Simvastatin also potentiated TNFalpha signaling as determined by increased TNFalpha-mediated E-selectin expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 75-83 16265685-5 2005 RESULTS: Simvastatin treatment significantly decreased serum CRP and TNF-a [from 14 +/- 6 to 7 +/- 3 mg/l (p = 0.025) and 30 +/- 5 to 16 +/- 4 pg/ml (p = 0.012), respectively], while quinapril had no significant changes in these 2 measures. Simvastatin 9-20 tumor necrosis factor Homo sapiens 69-74 16518530-7 2006 TNF-alpha demonstrated a faster linear trend in the simvastatin group, but the significant effect appeared late (p = 0.006). Simvastatin 52-63 tumor necrosis factor Homo sapiens 0-9 16511915-0 2006 Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Simvastatin 0-11 tumor necrosis factor Homo sapiens 99-126 16474306-7 2006 The results of the study document positive effect of half year treatment of patients with concomitant hypertension and diabetes with simvastatin (10-20 mg/day) in combination with ACEI and verapamil on metabolism of nitric oxide and plasma content of TNF-alpha which realizes independently from degree of hypolipidemic action of simvastatin. Simvastatin 133-144 tumor necrosis factor Homo sapiens 251-260 16465063-5 2005 Simvastatin suppressed MMP-9 at both the mRNA and protein levels as well as at the urokinase-type plasminogen activator protein level, resulting in the dramatic suppression of MMP-9 activity induced by tumor necrosis factor-alpha. Simvastatin 0-11 tumor necrosis factor Homo sapiens 202-229 16511915-3 2006 We investigated whether simvastatin could inhibit the expression of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) obtained from RA patients undergoing joint replacement therapy. Simvastatin 24-35 tumor necrosis factor Homo sapiens 132-159 16511915-3 2006 We investigated whether simvastatin could inhibit the expression of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha (TNF-alpha) in fibroblast-like synoviocytes (FLS) obtained from RA patients undergoing joint replacement therapy. Simvastatin 24-35 tumor necrosis factor Homo sapiens 161-170 16511915-8 2006 MTT assay revealed that simvastatin could inhibit proliferation of FLS induced by TNF-alpha. Simvastatin 24-35 tumor necrosis factor Homo sapiens 82-91 15458690-5 2004 Simvastatin and fenofibrate significantly lowered plasma levels of tumor necrosis factor alpha (TNF-alpha) by 13+/-4% and by 10+/-4%, respectively (P=0.009 and P=0.006, respectively) with a similar degree (P=0.614). Simvastatin 0-11 tumor necrosis factor Homo sapiens 67-94 15653378-0 2005 Simvastatin decreases myocardial tumor necrosis factor alpha content in heart transplant recipients. Simvastatin 0-11 tumor necrosis factor Homo sapiens 33-60 15653378-2 2005 We studied the effects of simvastatin treatment on myocardial tumor necrosis factor alpha (TNF-alpha) expression; TNF-alpha is a potent pro-inflammatory cytokine associated with hypertrophy and fibrosis in heart transplant recipients. Simvastatin 26-37 tumor necrosis factor Homo sapiens 62-89 15653378-2 2005 We studied the effects of simvastatin treatment on myocardial tumor necrosis factor alpha (TNF-alpha) expression; TNF-alpha is a potent pro-inflammatory cytokine associated with hypertrophy and fibrosis in heart transplant recipients. Simvastatin 26-37 tumor necrosis factor Homo sapiens 91-100 15653378-2 2005 We studied the effects of simvastatin treatment on myocardial tumor necrosis factor alpha (TNF-alpha) expression; TNF-alpha is a potent pro-inflammatory cytokine associated with hypertrophy and fibrosis in heart transplant recipients. Simvastatin 26-37 tumor necrosis factor Homo sapiens 114-123 15653378-8 2005 At the 24(th) week after transplantation, when compared with Week 1 values, we found a significant decrease in myocardium TNF-alpha content in the simvastatin group (15.0% +/- 2.3% vs 5.8% +/- 2.4%, p = 0.02) that was not observed in the placebo group (15.0% +/- 1.5% vs 12.0% +/- 2.6%, p = not significant). Simvastatin 147-158 tumor necrosis factor Homo sapiens 122-131 15653378-9 2005 CONCLUSION: Simvastatin treatment in heart transplant recipients decreased myocardium TNF-alpha expression. Simvastatin 12-23 tumor necrosis factor Homo sapiens 86-95 15537504-0 2004 Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Simvastatin 122-133 tumor necrosis factor Homo sapiens 0-27 15537504-11 2004 Simvastatin (0.1-10 mumol/l) concentration dependently inhibited TNFalpha-induced myofibroblast proliferation, invasion and MMP-9 secretion. Simvastatin 0-11 tumor necrosis factor Homo sapiens 65-73 15537504-12 2004 CONCLUSIONS: TNFalpha, acting predominantly via the TNF-R1 receptor, increased human atrial myofibroblast proliferation, invasion and MMP-9 secretion, all of which were inhibited by simvastatin. Simvastatin 182-193 tumor necrosis factor Homo sapiens 13-21 15520323-8 2004 The LPS-induced increases in neutrophil oxidative burst and plasma tumor necrosis factor-alpha concentrations were mitigated by simvastatin (P<0.05 versus placebo). Simvastatin 128-139 tumor necrosis factor Homo sapiens 67-94 15936988-2 2005 Simvastatin, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC). Simvastatin 0-11 tumor necrosis factor Homo sapiens 122-155 15936988-5 2005 In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin. Simvastatin 26-37 tumor necrosis factor Homo sapiens 119-128 15936988-5 2005 In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin. Simvastatin 200-211 tumor necrosis factor Homo sapiens 119-128 15458690-5 2004 Simvastatin and fenofibrate significantly lowered plasma levels of tumor necrosis factor alpha (TNF-alpha) by 13+/-4% and by 10+/-4%, respectively (P=0.009 and P=0.006, respectively) with a similar degree (P=0.614). Simvastatin 0-11 tumor necrosis factor Homo sapiens 96-105 15541048-4 2004 Diabetic subjects who had been receiving simvastatin treatment had TNF-alpha mRNA production similar to that of the healthy participants. Simvastatin 41-52 tumor necrosis factor Homo sapiens 67-76 15234187-0 2004 Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells. Simvastatin 0-11 tumor necrosis factor Homo sapiens 22-30 15234187-5 2004 In TNFalpha-stimulated HUVEC, simvastatin decreased VCAM-1 and ICAM-1 mRNA levels, inhibited TNFalpha-induced activation of nuclear factor kappaB (NF-kappaB) and enhanced expression of peroxisome proliferator-activated receptor alpha (PPARalpha). Simvastatin 30-41 tumor necrosis factor Homo sapiens 3-11 15193818-3 2004 RESULTS: Compared with diet alone, simvastatin significantly improved the percent flow-mediated dilator response to hyperemia and lowered plasma levels of tumor necrosis factor (TNF)-alpha, intercellular adhesion molecule type-1 (ICAM-1), serum levels of CRP, and fibrinogen (P<0.001, P<0.001, P=0.035, P<0.001 and P=0.014, respectively). Simvastatin 35-46 tumor necrosis factor Homo sapiens 155-188 15234187-5 2004 In TNFalpha-stimulated HUVEC, simvastatin decreased VCAM-1 and ICAM-1 mRNA levels, inhibited TNFalpha-induced activation of nuclear factor kappaB (NF-kappaB) and enhanced expression of peroxisome proliferator-activated receptor alpha (PPARalpha). Simvastatin 30-41 tumor necrosis factor Homo sapiens 93-101 15210062-5 2004 Pretreatment with simvastatin (30 or 60 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, the increased level of TNF-alpha and the decreased level of NO by LDL, but no effect on serum concentration of endogenous ADMA. Simvastatin 18-29 tumor necrosis factor Homo sapiens 134-143 15210062-7 2004 Pretreatment with simvastatin (0.1, 0.5, or 2.5 micromol/L) markedly decreased the level of TNF-alpha and the adhesion of monocytes to endothelial cells, but did not affect the concentration of endogenous ADMA and the activity of DDAH. Simvastatin 18-29 tumor necrosis factor Homo sapiens 92-101 15210062-8 2004 CONCLUSION: Simvastatin protect the vascular endothelium against the damages induced by LDL or ox-LDL in rats or cultured ECV304 cells, and the beneficial effects of simvastatin may be related to the reduction of inflammatory cytokine TNF-alpha level. Simvastatin 12-23 tumor necrosis factor Homo sapiens 235-244 15210062-8 2004 CONCLUSION: Simvastatin protect the vascular endothelium against the damages induced by LDL or ox-LDL in rats or cultured ECV304 cells, and the beneficial effects of simvastatin may be related to the reduction of inflammatory cytokine TNF-alpha level. Simvastatin 166-177 tumor necrosis factor Homo sapiens 235-244 15187114-8 2004 This appears to be a general mechanism because simvastatin also augments LPS-dependent activation of the TNF-alpha promoter, perhaps because the TNF-alpha promoter has C/EBP and AP-1 binding sites in a similar configuration to the IL-12p40 promoter. Simvastatin 47-58 tumor necrosis factor Homo sapiens 105-114 15187114-8 2004 This appears to be a general mechanism because simvastatin also augments LPS-dependent activation of the TNF-alpha promoter, perhaps because the TNF-alpha promoter has C/EBP and AP-1 binding sites in a similar configuration to the IL-12p40 promoter. Simvastatin 47-58 tumor necrosis factor Homo sapiens 145-154 15187114-9 2004 The fact that simvastatin potently augments LPS-induced IL-12p40 and TNF-alpha production has implications for the treatment of bacterial infections in statin-treated patients. Simvastatin 14-25 tumor necrosis factor Homo sapiens 69-78 15786696-5 2004 The aim of the study was to assess the influence of simvastatin on serum levels of proinflammatory cytokines such as IL-2 and TNFalpha in hypercholesterolemic patients. Simvastatin 52-63 tumor necrosis factor Homo sapiens 126-134 15193818-5 2004 Further, we observed that patients with the highest pretreatment TNF-alpha, ICAM-1, and CRP levels showed the greatest extent of reductions on simvastatin. Simvastatin 143-154 tumor necrosis factor Homo sapiens 65-74 15221496-8 2004 In the analysis of cytokines, while no significant change was observed in IL-6 levels, the TNF-alpha level was found to be significantly decreased after simvastatin treatment (from 77.9 +/- 31.6 pg/ml to 23.5 +/- 12.6 pg/ml [P = 0.021]). Simvastatin 153-164 tumor necrosis factor Homo sapiens 91-100 15221496-12 2004 Additionally, the presence of a negative correlation between TNF-alpha levels and the anabolic bone parameters suggests that a cytokine-lowering effect of simvastatin may also be involved in the remodeling process and could exert some additive beneficial effect on bone metabolism. Simvastatin 155-166 tumor necrosis factor Homo sapiens 61-70 14724693-4 2003 AIM: To examine the effects of simvastatin on IL-2 and TNFalpha levels in patients with hypercholesterolemia. Simvastatin 31-42 tumor necrosis factor Homo sapiens 55-63 14724693-12 2003 Subsequent simvastatin therapy caused further decrease in the TNFalpha serum concentration but this difference did not achieve statistical significance. Simvastatin 11-22 tumor necrosis factor Homo sapiens 62-70 14629460-9 2003 Furthermore, GGTI-286, but not FTI-277, mimicked the effect of simvastatin by increasing the TNF-alpha-mediated overexpression of E-selectin. Simvastatin 63-74 tumor necrosis factor Homo sapiens 93-102 12753293-9 2003 In the presence of simvastatin t-PA synthesis in control and TNF-alpha-treated cells dose-dependently increased, reaching 5.8-fold and 7.7-fold higher t-PA levels, respectively, at 5 micromol/L simvastatin after 48 hours. Simvastatin 19-30 tumor necrosis factor Homo sapiens 61-70 14629460-7 2003 RESULTS: Pretreatment with simvastatin, fluvastatin or pravastatin potentiated the TNF-alpha and LPS-induced expression of E-selectin and VCAM-1, and mevalonate reversed the potentiating effect of these statins. Simvastatin 27-38 tumor necrosis factor Homo sapiens 83-92 12753293-0 2003 Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Simvastatin 0-11 tumor necrosis factor Homo sapiens 87-114 12885745-10 2003 Furthermore, plasma concentrations of tumor necrosis factor-alpha, interleukin-6, and brain natriuretic peptide were significantly lower in the simvastatin group compared with the placebo group. Simvastatin 144-155 tumor necrosis factor Homo sapiens 38-65 12753293-4 2003 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, on the expression of t-PA, PAI-1 and tissue factor after activation of the cells with tumor necrosis factor-alpha (TNF-alpha). Simvastatin 128-139 tumor necrosis factor Homo sapiens 227-254 12753293-4 2003 METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, on the expression of t-PA, PAI-1 and tissue factor after activation of the cells with tumor necrosis factor-alpha (TNF-alpha). Simvastatin 128-139 tumor necrosis factor Homo sapiens 256-265 12753293-9 2003 In the presence of simvastatin t-PA synthesis in control and TNF-alpha-treated cells dose-dependently increased, reaching 5.8-fold and 7.7-fold higher t-PA levels, respectively, at 5 micromol/L simvastatin after 48 hours. Simvastatin 194-205 tumor necrosis factor Homo sapiens 61-70 12753293-10 2003 Simvastatin dose-dependently suppressed PAI-1 production in both control and TNF-alpha-treated cells. Simvastatin 0-11 tumor necrosis factor Homo sapiens 77-86 12753293-11 2003 At 5 micromol/L, simvastatin lowered PAI-1 synthesis 3.4-fold and 4.0-fold, respectively, thereby also completely suppressing the TNF-alpha effect itself. Simvastatin 17-28 tumor necrosis factor Homo sapiens 130-139 12753293-12 2003 Similarly, simvastatin down-regulated the expression of tissue factor and also completely opposed the TNF-alpha-induced tissue factor expression. Simvastatin 11-22 tumor necrosis factor Homo sapiens 102-111 12753293-14 2003 Also, simvastatin reduced NF-kappa B- and AP-1-dependent reporter gene activity in TNF-alpha-treated HT-1080 fibrosarcoma cells and reduced the nuclear levels of p50-NF-kappa B, p65-NF-kappa B, and the AP-1 components c-fos and c-jun in HMC. Simvastatin 6-17 tumor necrosis factor Homo sapiens 83-92 11428539-7 2001 Furthermore, administration of simvastatin tended to lower plasma levels of plasminogen activator inhibitor type-1 and tumor necrosis factor-alpha [by 20+/-44 and 13+/-29%, respectively (P= 0.066 and 0.110, respectively)]. Simvastatin 31-42 tumor necrosis factor Homo sapiens 76-146 12615677-7 2003 Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs). Simvastatin 10-21 tumor necrosis factor Homo sapiens 81-114 12615677-7 2003 Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs). Simvastatin 10-21 tumor necrosis factor Homo sapiens 214-223 12472772-7 2003 Tumor necrosis factor-alpha (TNF-alpha)-primed neutrophils released 26.7 +/- 2.8 nmol O2-/0.75 x 106 PMN/45 min and 10 micromol/L simvastatin reduced this amount to 18.0 +/- 2.1 nmol. Simvastatin 130-141 tumor necrosis factor Homo sapiens 0-27 12472772-7 2003 Tumor necrosis factor-alpha (TNF-alpha)-primed neutrophils released 26.7 +/- 2.8 nmol O2-/0.75 x 106 PMN/45 min and 10 micromol/L simvastatin reduced this amount to 18.0 +/- 2.1 nmol. Simvastatin 130-141 tumor necrosis factor Homo sapiens 29-38 12472772-14 2003 By FACS, simvastatin decreased TNF-alpha-mediated ANCA antigen translocation (from 219 +/- 33 to 180 +/- 35 MFI for PR3 and 24.0 +/- 2.4 to 18.3 +/- 1.1 for MPO). Simvastatin 9-20 tumor necrosis factor Homo sapiens 31-40 34812477-8 2022 Furthermore, simvastatin administration significantly decreased ROS production and the concentrations of TNF-alpha and IL-6, which were significantly increased in neutrophils isolated from the SP group. Simvastatin 13-24 tumor necrosis factor Homo sapiens 105-114 11693755-9 2001 Simvastatin reduced the TNF-alpha-related binding activity of neutrophil cytosolic proteins to eNOS mRNA, which was associated with its protective effect on eNOS protein expression. Simvastatin 0-11 tumor necrosis factor Homo sapiens 24-33 10933353-7 2000 In patients with diet plus simvastatin, significant decreases of total cholesterol (-27%, p<0.02), low density lipoprotein-cholesterol (-33%, p<0.02), and monocyte expression of TNF (-49%, p<0.02) and IL-1beta (-35%, p<0.02) were observed. Simvastatin 27-38 tumor necrosis factor Homo sapiens 184-187 10933353-8 2000 At the end of treatment period, patients treated with simvastatin had lower cholesterol and monocyte TNF and IL-1beta than did patients assigned to diet alone. Simvastatin 54-65 tumor necrosis factor Homo sapiens 101-104 10933353-9 2000 CONCLUSION: This study suggests that simvastatin possesses anti-inflammatory activity via the inhibition of pro-inflammatory cytokines TNF and IL-1beta expressed by monocytes. Simvastatin 37-48 tumor necrosis factor Homo sapiens 135-138 35308127-0 2022 Beneficial effect of simvastatin on human umbilical vein endothelial cells gap junctions induced by TNF-alpha. Simvastatin 21-32 tumor necrosis factor Homo sapiens 100-109 35123844-11 2022 Western blot analysis showed that oxidized LDL as well as TNF-alpha and IL-1beta activated the signaling of MAPKs and NF-kappab in LF cells, and that simvastatin treatment reduced the phosphorylation of all signaling. Simvastatin 150-161 tumor necrosis factor Homo sapiens 58-67